Endovia Health Sciences Regulatory Approval
Endovia Health Sciences announced that the FDA's Center for Veterinary Medicine determined its investigational drug CannEpil qualifies as a 'minor use' under the MUMS program for canine bone cancer pain. This designation allows the company to pursue a conditional approval pathway, which facilitates earlier market availability while additional effectiveness data is collected. The company is targeting a potential U.S. veterinary product launch in 2027.
- Counterparty
- Lupvindol BioSciences